TG Therapeutics to Present at the Jefferies 2020 Healthcare Conference
TG Therapeutics, Inc. (NASDAQ: TGTX) announced that its Executive Chairman and CEO, Michael S. Weiss, will participate in a fireside chat at the Jefferies 2020 Healthcare Conference on June 3, 2020, at 10:00 AM ET. This event will be virtual, and a live webcast can be accessed on the Company’s Investors & Media page. TG Therapeutics focuses on developing therapies for B-cell malignancies and autoimmune diseases, including the Phase 3 clinical development of ublituximab and umbralisib.
- None.
- None.
NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the Jefferies 2020 Healthcare Conference, being held virtually. The fireside chat is scheduled to take place on Wednesday, June 3, 2020 at 10:00 AM ET.
A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing multiple therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an oral, once-daily dual inhibitor of PI3K-delta and CK1-epsilon, which may lead to a differentiated safety profile. Both ublituximab and umbralisib, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought into Phase 1 clinical development its anti-PD-L1 monoclonal antibody, cosibelimab (TG-1501), its covalently-bound Bruton’s Tyrosine Kinase (BTK) inhibitor, TG-1701, as well as its anti-CD47/CD19 bispecific antibody, TG-1801. TG Therapeutics is headquartered in New York City.
CONTACT:
Jenna Bosco
Senior Vice President,
Corporate Communications
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: ir@tgtxinc.com
FAQ
When is Michael S. Weiss speaking at the Jefferies 2020 Healthcare Conference?
Where can I watch the TG Therapeutics fireside chat?
What is the focus of TG Therapeutics?
What therapies are TG Therapeutics developing?
What is the stock symbol for TG Therapeutics?
